Health Ministry Recommends Actemra’s Alternative Medicines for COVID-19 Patients

The Federal Health Ministry has recommended Baricitinib and Tofacitinib as alternative drugs to intravenous Actemra for the treatment of critically ill COVID-19 patients.

In a statement, the Health Ministry said that a shortage of Actemra has been reported all over the world including Pakistan and various public healthcare agencies have been prescribing alternatives to Actemra.

Speaking to a news channel, a spokesperson for the Health Ministry also expressed confidence in Baricitinib and Tofacitinib for the treatment of seriously ill Coronavirus patients.

Roche, the sponsor of Actemra, has also confirmed the shortage of medicine due to increased global demand in response to the Coronavirus pandemic.

The Swiss multinational healthcare company said that the shortage of intravenous Actemra across the world will continue for the next several weeks.

Actemra is an immunosuppressive drug that is used for the treatment of rheumatoid arthritis and systemic juvenile idiopathic arthritis, a severe form of arthritis in children.

In June this year, the US Food and Drug Authority (FDA) officially granted Emergency Use Authorization (EUA) to Actemra. Since then, the worldwide stocks of the drug have been gradually decreasing as the Coronavirus pandemic rages on.

Related posts

Los Angeles County Reinstates Mask Mandate for Healthcare Facilities

Los Angeles County healthcare facilities have reintroduced a mask mandate due to a significant surge…
Read more

Cop martyred in attack on polio team in Bannu

LAKKI MARWAT: A policeman accompanying the polio vaccination team was martyred when unidentified…
Read more

Porton Down: Which next pandemic is UK's top secret laboratory trying to prevent?

Passing through stringent security measures at the remote facility, rare access has been granted to…
Read more
Become a Trendsetter
Sign up for Davenport’s Daily Digest and get the best of Davenport, tailored for you.

Leave a Reply

Your email address will not be published. Required fields are marked *